Prevention & lipidsCohort study
Lipoprotein(a) and residual cardiovascular risk in statin-treated patients
- Cohort study
- UK Biobank
Authors' conclusion
In a statin-treated population at high CV risk, moderately elevated Lp(a) levels (>46.8 nmol/L) below current guideline thresholds are associated with significantly increased risk of CV events, with a substantially stronger effect observed in those without established ASCVD.
Study context
- Population
- Statin-treated patients aged ≥45 years with established atherosclerotic cardiovascular disease (ASCVD) or T2DM, UK Biobank
- Participants
- 17,376 patients
- Exposure
- Upper vs lower Lp tertile
- Outcome
- MACE:
- Non-fatal MI
- Non-fatal stroke
- CV mortality
Main finding
As reported in the abstract
MACE
Upper vs lower Lp(a)-tertile: 20% higher risk of major adverse cardiovascular events (MACE)
p<0.01
Observational data: associations, not effects.
Further findings
Hospitalization for myocardial infarction (MI)
- Upper vs lower tertile: 27% higher risk
- P < 0.05
Coronary revascularization
- Upper vs lower tertile: 34% higher rate
- P < 0.001
Cardiovascular (CV) mortality
- Upper vs lower tertile: 30% increased CV mortality
- P < 0.05
MACE dose-response, by baseline ASCVD status
- More pronounced effect of Lp(a) on MACE risk in individuals without established ASCVD
Original publication
Lipoprotein(a) and residual cardiovascular risk in statin-treated patients. Eur J Prev Cardiol. Published 4 June 2026. doi:10.1093/eurjpc/zwag296
Summarised from the published abstract; every number is checked against it